Thank you for Subscribing to Life Science Review Weekly Brief
Opterion Health AG has announced that they have appointed Björn Englund as the company's CEO.
FREMONT, CA : Opterion Health AG, a preclinical Swiss life science organization, producing the first innovative peritoneal dialysis (PD) solution in the last two decades, recently announced that they had appointed Björn Englund as CEO. He will take over as CEO in April 2021, replacing Guido Grentzmann, the company's founder and CSO, who will concentrate his efforts on the firm's scientific development and preparation to start Phase I.
Björn Englund has been appointed CEO of Opterion Health AG by the Board of Directors, effective from April 6, 2021. He began his professional career in 1991 as a sales agent for the Gambro Distributor in Saudi Arabia, took over further responsibilities, and became the Managing Director of Gambro Healthcare Sweden AB in 1996. Englund left Gambro in 2006 to join Euromedic as Vice President of the Dialysis Section, where he remained until 2011. He was President and CEO of DaVita EMEA for the next six years before being promoted to COO of DaVita International in 2017. He left DaVita in 2018 and has since worked for EQT in Stockholm as an Industrial Advisor.
David Ebsworth, Chairman of Opterion, comments, "I am delighted that Björn is joining our company. Thanks to his solid background in dialysis and his strong network in the industry, he is predestined to drive Opterion to further success and to lead the company in such a way that ensures our ambitious milestones can be achieved."
"After many years of acting as both CEO/CSO of Opterion, it is now time to fully focus on the scientific activities of Opterion my true passion. Björn joining Opterion as our new CEO is a great step forward for Opterion to become a true player in peritoneal dialysis therapy development, and it is a privilege that Björn has decided to join the company," adds Guido Grentzmann.
Björn Englund says, "I am incredibly excited to be joining Opterion and help to bring to the market this novel peritoneal dialysis solution that will improve the quality of life of so many patients. The team has done a phenomenal job so far and I look forward to helping to unlock the full potential of this much-needed innovation."